| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d5de66fcc7c37934b48c684ca26e9cc0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55561
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55555
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2710-20022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-515
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-525
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-57 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-095 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-025
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-02 |
| filingDate |
2001-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2007-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca3ac23855db5f3fde64c249488d05ba
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cbfe5409503bcf5e6fa8abc0aa39b5a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_856d03c7224a91df86486d88a60fdcb3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e3aa806cee9562fdeae69e489646b06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe9389851a41d40df96abcaa36c0e0ab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2425425635643211ea03e2c5dad4a958
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84e57bec59907e8d418918f1632d4b62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2de08d170ef6b6df5bddb552944733d |
| publicationDate |
2007-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7202034-B2 |
| titleOfInvention |
Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses |
| abstract |
The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22–45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22–35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22–35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length. The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22–35 amino acid long peptides. The invention further provides clinically relevant approaches for vaccination and/or treatment of subjects against HPV. The invention also provides methods and uses suited to treat subjects suffering from progressive lesions and/or cervical cancer. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019231863-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9603920-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426458-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9562075-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013072768-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10702598-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010196353-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11524063-B2 |
| priorityDate |
2000-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |